Does anyone know what's going on behind the scenes? The continuing arguments about financing, patents, science, etc. are questions that are apparently cannot be answered by posters on this board.
How are potential investors suppose to commit to investing capital in a biotech with so many unanswered questions? Before the "market" decides commercialization of KBLB products is viable and successfully progressing toward that goal, there has to be more than a PR that fails to even mention the correlation between the science "news" and commercial products that could be produced.
The experts on this board can't agree on what the continuing science means, how can KBLB expect the "market" to embrace it's potential? Will the coming CC provide answers to the questions that the market demands for new investment? Will the CC even address these issues in a intelligent manner that current investors desire, or will it leave the market even more confused than ever?